Multidisciplinary management of advanced primary and metastatic breast cancer

Cancer

Volumn 74, Issue 1 S, 1994, Pages 416-423

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast cancer; chemotherapy; hormone therapy

Indexed keywords

ADOZELESIN; AMINOGLUTETHIMIDE; AMONAFIDE; ANDROGEN; ANTHRAQUINONE DERIVATIVE; ANTIESTROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; CAMPTOTHECIN; CLOMIFENE; CYCLOPHOSPHAMIDE; DANAZOL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GESTAGEN; GONADORELIN DERIVATIVE; IRINOTECAN; LEUPRORELIN; MEGESTROL ACETATE; METHOTREXATE; MIFEPRISTONE; MILTEFOSINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; RHIZOXIN; TAMOXIFEN; UNINDEXED DRUG;

BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATORY DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 0028245312     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.2820741329     Document Type: Article

References (51)

1. Locally advanced breast cancer: a review including the M. D. Anderson Experience
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
3. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10‐year results of a Southwest Oncology Group study
4. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer
5. Combined therapy of stage III adenocarcinoma of the breast [abstract]
6. 4) breast cancer
7. Combined chemotherapy and radiotherapy for locally advanced breast cancer
8. Multimodal treatment for locally advanced breast cancer. Results of chemotherapy‐radiotherapy versus chemotherapy‐surgery
9. Multimodal treatment of locoregionally advanced breast cancer
10. Concurrent chemotherapy and radiotherapy for nonmetastatic, stage IV breast cancer: a pilot study by the Southeastern Cancer Study Group
11. Results of combined treatment of patients with locally advanced breast cancer
12. 4 breast cancer: factors affecting results in combined modality treatments
13. An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast cancer
14. Adjuvant chemo‐ and hormonal therapy in locally advanced breast cancer: a randomized clinical study
15. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results
16. Management of nonresectable locally advanced (stage III) breast cancer: an ECOG trial [abstract]
17. Combination chemotherapy prior to surgery or radiotherapy in locally advanced breast cancer
18. Essai pilote de chimiothérapie néo‐adjuvante dans le cancer
19. Multidisciplinary therapy for locally advanced breast cancer (LABC): an update [abstract]
20. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA‐IIIB)
21. Induction chemotherapy for stage III primary breast cancer
22. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer
23. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
24. Inflammatory breast carcinoma treated by radical radiotherapy
25. Initial chemoimmunotherapy in inflammatory carcinoma of the breast
26. Aggressive combined modality therapy for advanced local‐regional breast carcinoma
27. Management of inflammatory carcinoma of the breast: a combined modality approach
28. Preoperative chemotherapy in the treatment of inflammatory breast cancer
29. Neo‐adjuvant chemotherapy in the conservative management of breast cancers: study on 205 patients
30. Traitement combiné des cancers inflammatoires due sein par chimiothérapie suivie de chirurgie et de radiothérapie
31. Résultats du traitement des cancers inflammatoires due sein par une association thérapeutique comportant une chimiothérapie initiale
32. Traitements par chimiothérapie premiere de cancers du sein MO, localement advances (T3–T4) ou s'accompagnant de signes inflammatoires locaux
33. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer: combined modality approach in 178 patients
34. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Instirut Gustave‐Roussy
35. Two years of high‐dose cyclophosphamide and 5‐fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas: a phase II study of 25 cases with a median follow‐up of 35 months
36. Inflammatory breast cancer: a review
37. Inflammatory carcinoma of the breast: results of a combined‐modality approach—M. D. Anderson Cancer Center experience
38. Early results of the British Columbia breast cancer preoperative (neo‐adjuvant) chemotherapy trial
39. Dose‐intensive therapy in breast cancer
40. Natural history of untreated breast cancer (1805–1933): comparison of untreated and treated cases according to histological grade of malignancy
41. Current status of endocrine treatment of carcinoma of the breast
42. Principles in the management of metastatic disease
43. The importance of dose‐response in cytotoxic therapy for breast cancer
44. Overview of new treatments for breast cancer
45. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
46. Monoclonal antibodies in diagnosis and therapy